Nyxoah (NYXH) has released an update.
Nyxoah SA, a medical tech company targeting sleep apnea treatments, reported a 29% sales growth in the first half of 2024 and has completed its FDA regulatory submission, expecting U.S. approval by the end of 2024. The company has strengthened its U.S. commercial team in preparation for the market launch, supported by over €85 million in newly raised capital. Despite these advancements, the company has reported a net loss for the first half of 2024.
For further insights into NYXH stock, check out TipRanks’ Stock Analysis page.
